Selinexor in Combination With MTX+Ritu to Treat R/R CNSL

Official title

Selinexor in Combination With Methotrexate and Rituximab for Relapsed /Refractory Central Nervous System (CNS) Lymphoma

Overview

This is a single-arm and open-label study to explore X+MTX+Ritu (ATG-010, Methotrexate, Rituximab) regimen in Relapse refractory PCNSL patients. Approximately 30 patients will be enrolled in the study. In dose escalation phase, patients with Relapse refractory PCNSL will be treated with X+MTX+Ritu regimen and escalating doses of oral ATG-010 weekly in a 3+3 design. Then a phase 2 expansion at the recommended dose level based on phase 1b trial will be conducted to evaluate the efficacy, safety and tolerability.

Detailed description

In dose escalation phase, patients with Relapse refractory PCNSL will be treated with X+MTX+Ritu regimen （Methotrexate 3.5 g/m2, d1; Rituximab 375 mg/m2, d0）and escalating doses of oral ATG-010 weekly in a 3+3 design. ATG-010 dose level (DL) 1, 2 and 3 are 60, 80 and 100mg respectively respectively on day 1,8,15,22 for 28-days cycle.

The phase 2 expansion at the recommended dose level based on phase 1b trial. The total 6 cycles, 28 days per cycle . And, Subjects participating in the study will undergo a screening period（up to 21days）, a treatment period, and a follow-up period. The screening period is a maximum of 21 days before treatment period, And will be followed by 6 cycles of combination treatment（28 days per cycle）.

partial remission(PR) patients after induction treatment will continue ATG-010 maintenance up to 1 year or until disease progression, intolerable toxicity, death.

Interventions

• Drug Selinexor
  Selinexor dose escalation: 60,80,100mg respectively on day 1,8,15,22 for 28 days cycles, and dose expansion at the RP2D of Selinexor. PR patients after induction treatment will continue ATG-010 maintenance up to 1 year or until disease progression, intolerable toxicity, death.
• Drug Rituximab
  Rituximab 375 mg/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
• Drug Methotrexate
  high-dose Methotrexate 3.5 g/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.

Primary outcome measures

• Dose Escalation: Maximum Tolerated Dose (MTD) of Selinexor [Time frame: Assessed from the date of first dose of study treatment to the first cycle ends (maximum 21days)]
• Dose Escalation: Recommended Phase 2 Does (RP2D) of Selinexor [Time frame: Assessed from the date of first dose of study treatment to the first cycle ends (maximum 21days)]
• Objective Response Rate (ORR) [Time frame: Cycle 1 Day 1 (each cycle consists of maximum 21 days) until a CR, CRu or PR (up to 18 cycles(each cycle is 21 days)).]

Secondary outcome measures (4)

• Duration of Response (DOR) [Time frame: From first dose of study drug administration to end of treatment, up to 18 cycles(each cycle is 21 days)]
• Overall Survival (OS) [Time frame: up to 12 months]
• Progression-Free Survival (PFS) [Time frame: up to 12 months]
• Number of Participants with Adverse Events [Time frame: From first dose of study drug administration to end of treatment (up to 18 cycles(each cycle is 21 days))]

Eligibility criteria

Inclusion criteria

• Patients must meet all of the following inclusion criteria to be eligible to enroll in this study:

• Participants must be able to understand and be willing to sign a written informed consent document.
• Men and woman who are 18-75 years old on the day of consenting to the study.
• Histologically documented PCNSL and SCNSL secondary to histologically documented systemic diffuse large B-cell lymphoma (DLBCL).
• Patients must have relapsed/refractory PCNSL or relapsed/refractory SCNSL.
• Patients must have response or remain stable disease for 2 months to prior methotrexate-based regimen.
• Patients who had prior autologous hematopoietic stem cell transplantation are eligible.
• Patients with parenchymal lesions must have unequivocal evidence of disease progression on imaging (MRI of the brain or head CT) 28 days prior to cycle1 day 1(C1D1). For patients with leptomeningeal disease only, CSF cytology must document lymphoma cells.
• Participants must have an Eastern Cooperative Oncology Group performance status of 0-3.
• Participants must have adequate bone marrow and organ function shown by:

• Absolute neutrophil count (ANC) ≥ 1.0 x 10\^9/L
• Platelets ≥ 75 x 10\^9/L and no platelet transfusion within the past 14 days prior to study registration c Hemoglobin (Hgb) ≥ 8 g/dL and no red blood cell (RBC) transfusion within the past 14 days prior to study registration
• International Normalized Ratio (INR) ≤ 1.5 and PTT (aPTT) ≤ 1.5 times the upper limit of normal.
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal.
• Serum bilirubin ≤ 1.5 times the upper limit of normal; or total bilirubin ≤ 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert Syndrome.
• Calculated creatinine clearance(CrCl)≥50ml/min using the Cockcroft-Gault equation or 24-hour urine collection.
• Life expectancy of > 3 months.

Exclusion criteria

• Patients with SCNSL actively receiving treatment for extra-CNS disease are excluded.
• Lymphoma patients with only intraocular involvement.
• Pathological diagnosis of PCNSL is T-cell lymphoma.
• Patients with disease progression within 6 months of prior methotrexate-containing regimen.
• patients only had received stereotactic radiation therapy as prior treatment.
• Patients have received chemotherapy, monoclonal antibodies or targeted anticancer therapy within 21 days or 5 half-lives, whichever is shorter, prior to C1D1.
• Patients with active, unstable cardiovascular diseases, fits any of the following:

• myocardial infarction within 6 months prior to the study enrollment
• unstable angina within 3 months prior to the study enrollment
• Uncontrolled clinically-significant conduction abnormalities (e.g., ventricular tachycardia, ventricular fibrillation, etc.)
• Congestive heart failure (CHF) of New York Heart Association (NYHA) ≥ Grade 3
• Echocardiography showing left ventricular ejection fraction less than 50%
• Uncontrolled active infection within 1 week prior to the first dose of study drug.
• Known active hepatitis B, or C infection or HIV infection; Note: Hepatitis B virus (HBV) surface antigen (HBsAg) and or hepatitis B core antibody-positive but undetectable HBV DNA or Hepatitis C virus (HCV) antibody positive but hepatitis C virus RNA undetectable are allowed.
• Active GI dysfunction interfering with the ability to swallow tablets, or any GI dysfunction that could interfere with absorption of study treatment.
• Prior exposure to a selective inhibitor of nuclear export(SINE) compound, including selinexor.
• Serious, active psychiatric, or medical conditions which, in the opinion of the Investigator, could interfere with study treatment.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

China · 5 centers

• The First Affiliated Hospital Of Anhui Medical University — Hefei
• Beijing Tiantan Hospital, Capital Medical University — Beijing
• The First Affiliated Hospital Of Fujian Medical University — Fuzhou
• Oncology Department of The First Affiliated Hospital of Zhengzhou University — Zhengzhou
• Department of Hematology, Huashan Hospital, Fudan University — Shanghai

Identifiers

NCT: NCT05698147 · KY2022-881

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗